Abstract
SummaryGiven the growing use of immune checkpoint inhibitor (ICI) therapy in oncology, the prevalence of endocrine side effects is rapidly increasing. As clinicians are nowadays frequently confronted with these side effects in routine clinical care, awareness, better knowledge of endocrine irAEs and their clinical presentation and diagnosis is crucial for an adequate management. In this short-review we give a compact overview of the recent recommendations for the management of endocrine irAE related to ICIs and highlight difficulties and uncertainties in current clinical practice.
Highlights
The inhibition of immune checkpoints by using monoclonal antibodies against cytotoxic-T-lymphocyteassociated antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) has revolutionized anti-cancer therapy in recent years and emerged as a cornerstone in the treatment of a constantly growing number of solid cancer types
Better knowledge of endocrine immune-related adverse events (irAE) and their clinical presentation and diagnosis is crucial for adequate management
In this short review we give a compact overview of the recent recommendations for the management of endocrine irAE related to immune checkpoint inhibitor (ICI) and highlight difficulties and uncertainties in current clinical practice
Summary
The inhibition of immune checkpoints by using monoclonal antibodies against cytotoxic-T-lymphocyteassociated antigen 4 (CTLA-4) or programmed cell death 1 (PD-1) has revolutionized anti-cancer therapy in recent years and emerged as a cornerstone in the treatment of a constantly growing number of solid cancer types. In this short review we give a compact overview of the recent recommendations for the management of endocrine irAE related to ICIs and highlight difficulties and uncertainties in current clinical practice. It is more frequent in patients receiving anti-PD-1 directed treatment [6], probably due to the high expression of PD-1 receptors in thyroid cells [7].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
